타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody) Roche / Genentech·Colorectal Cancer 143 trials |
|---|---|---|---|
Overview Program | Datroway (datopotamab deruxtecan-dlnk) | Tevimbra (tislelizumab) | Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody |
Overview Company | Daiichi Sankyo / AstraZeneca | BeOne Medicines | Roche / Genentech |
Overview Modality | ADC | ANTIBODY | ANTIBODY |
Overview Target | TROP2 | PD-1 | Colorectal Cancer |
Overview Indication | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy | Triple-Negative Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. | — |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. | — |
Positioning Development positioning | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy | 1L–2L gastroesophageal, regimen-dependent | — |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) | — | — |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | — | — |
Technology DAR | DAR 4 | — | — |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. | PD-1 + ) CD8 + T cells follow |
PK/PD Half-life | — | ~20 days class range | — |
PK/PD Species | — | OS/PFS, radiographic response | — |
PK/PD Animal (cat.) | — | Human | — |
Toxicology Species | Rat, Hamster | — | — |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Clinical Selected reported efficacy | ORR 64% | — | — |
Clinical Reported ORR | 64% vs 30% (chemotherapy) | — | — |
Clinical Reported PFS | 10.8 months vs 5.6 months (chemotherapy) | — | — |
Clinical Reported OS | 23.7 months vs 18.7 months (chemotherapy) | — | — |
Clinical Result source | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT05374512 | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd) Daiichi Sankyo / AstraZeneca·TROP2 50 trials | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody) Roche / Genentech·Colorectal Cancer 143 trials |
|---|---|---|---|
Overview Program | Datroway (datopotamab deruxtecan-dlnk) | Tevimbra (tislelizumab) | Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody |
Overview Company | Daiichi Sankyo / AstraZeneca | BeOne Medicines | Roche / Genentech |
Overview Modality | ADC | ANTIBODY | ANTIBODY |
Overview Target | TROP2 | PD-1 | Colorectal Cancer |
Overview Indication | HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior therapies; first-line TNBC unsuitable for PD-1/PD-L1 therapy. Consult current US label. | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy | Triple-Negative Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. | — |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. | — |
Positioning Development positioning | Indication-specific; includes 1L TNBC unsuitable for PD-1/PD-L1 therapy | 1L–2L gastroesophageal, regimen-dependent | — |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) | — | — |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | — | — |
Technology DAR | DAR 4 | — | — |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. | PD-1 + ) CD8 + T cells follow |
PK/PD Half-life | — | ~20 days class range | — |
PK/PD Species | — | OS/PFS, radiographic response | — |
PK/PD Animal (cat.) | — | Human | — |
Toxicology Species | Rat, Hamster | — | — |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Clinical Selected reported efficacy | ORR 64% | — | — |
Clinical Reported ORR | 64% vs 30% (chemotherapy) | — | — |
Clinical Reported PFS | 10.8 months vs 5.6 months (chemotherapy) | — | — |
Clinical Reported OS | 23.7 months vs 18.7 months (chemotherapy) | — | — |
Clinical Result source | FDA approval report 2026-05-22 — TROPION-Breast02 (NCT05374512) | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | — | No active/completed counts |
Clinical Trial ref | NCT05374512 | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — |
추천 비교
추천 비교